$CLDX
Celldex Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000110465923055992 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $268.0K $967.0K
YoY Change 64.42% 455.75%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.221M $6.640M
YoY Change 0.94% -3.92%
% of Gross Profit
Research & Development $26.25M $26.80M
YoY Change 26.63% 57.12%
% of Gross Profit
Depreciation & Amortization $756.0K $726.0K
YoY Change 2.02% -10.48%
% of Gross Profit
Operating Expenses $26.25M $26.80M
YoY Change 26.63% 57.12%
Operating Profit -$33.21M -$32.47M
YoY Change -8.77% 39.62%
Interest Expense $2.703M $3.110M
YoY Change 589.54% 1402.42%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$30.50M -$29.36M
YoY Change -15.28% 27.38%
Income Tax
% Of Pretax Income
Net Earnings -$30.50M -$29.36M
YoY Change -15.28% 27.38%
Net Earnings / Revenue -11381.34% -3036.3%
Basic Earnings Per Share -$0.65 -$0.62
Diluted Earnings Per Share -$0.65 -$0.62
COMMON SHARES
Basic Shares Outstanding 47.25M 47.21M
Diluted Shares Outstanding 47.25K 47.21K

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $252.7M $278.4M
YoY Change -29.18% -26.83%
Cash & Equivalents $28.22M $54.12M
Short-Term Investments $224.5M $224.3M
Other Short-Term Assets $12.01M $9.896M
YoY Change 8.5% -0.92%
Inventory
Prepaid Expenses
Receivables $118.0K $1.314M
Other Receivables $0.00 $0.00
Total Short-Term Assets $264.8M $289.6M
YoY Change -28.03% -25.88%
LONG-TERM ASSETS
Property, Plant & Equipment $3.938M $3.995M
YoY Change 5.18% 14.67%
Goodwill
YoY Change
Intangibles $27.19M $27.19M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets $107.0K $104.0K
YoY Change 2.88% 0.0%
Total Long-Term Assets $34.49M $34.92M
YoY Change -1.4% 4.74%
TOTAL ASSETS
Total Short-Term Assets $264.8M $289.6M
Total Long-Term Assets $34.49M $34.92M
Total Assets $299.3M $324.5M
YoY Change -25.72% -23.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $881.0K $3.374M
YoY Change -2.33% 231.11%
Accrued Expenses $12.26M $9.374M
YoY Change 9.15% 1.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.65M $15.22M
YoY Change -47.76% 4.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.403M $4.403M
YoY Change -17.44% -58.22%
Total Long-Term Liabilities $4.403M $4.403M
YoY Change -17.44% -58.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.65M $15.22M
Total Long-Term Liabilities $4.403M $4.403M
Total Liabilities $21.77M $21.78M
YoY Change -42.5% -16.04%
SHAREHOLDERS EQUITY
Retained Earnings -$1.316B -$1.285B
YoY Change 9.41% 10.17%
Common Stock $1.591B $1.586B
YoY Change 1.47% 1.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $277.5M $302.7M
YoY Change
Total Liabilities & Shareholders Equity $299.3M $324.5M
YoY Change -25.72% -23.47%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$30.50M -$29.36M
YoY Change -15.28% 27.38%
Depreciation, Depletion And Amortization $756.0K $726.0K
YoY Change 2.02% -10.48%
Cash From Operating Activities -$27.20M -$28.60M
YoY Change 22.26% 16.73%
INVESTING ACTIVITIES
Capital Expenditures $410.0K $585.0K
YoY Change -160.92% 1.74%
Acquisitions
YoY Change
Other Investing Activities $1.574M $53.15M
YoY Change -93.94% 385.2%
Cash From Investing Activities $1.164M $52.57M
YoY Change -95.4% 406.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 133.0K 694.0K
YoY Change 87.32% 128.29%
NET CHANGE
Cash From Operating Activities -27.20M -28.60M
Cash From Investing Activities 1.164M 52.57M
Cash From Financing Activities 133.0K 694.0K
Net Change In Cash -25.90M 24.69M
YoY Change -933.3% -278.3%
FREE CASH FLOW
Cash From Operating Activities -$27.20M -$28.60M
Capital Expenditures $410.0K $585.0K
Free Cash Flow -$27.61M -$29.19M
YoY Change 27.98% 16.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5333000
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4403000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000744218
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-15006
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
CELLDEX THERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3191702
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Perryville III Building
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
53 Frontage Road
CY2023Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 220
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hampton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08827
CY2023Q1 dei City Area Code
CityAreaCode
908
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
200-7500
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $.001
CY2023Q1 dei Trading Symbol
TradingSymbol
CLDX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47252469
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54123000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29429000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
224264000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
275523000
CY2023Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1314000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
347000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9896000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12394000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
289597000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
317693000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3995000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3747000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3633000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4001000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27190000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27190000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2023Q1 us-gaap Assets
Assets
324519000
CY2022Q4 us-gaap Assets
Assets
352735000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3374000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3340000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9374000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12835000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1493000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1445000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
978000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
990000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15219000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18610000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2157000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2588000
CY2023Q1 us-gaap Liabilities
Liabilities
21779000
CY2022Q4 us-gaap Liabilities
Liabilities
26531000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47244681
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47244681
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47200695
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47200695
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
47000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1585863000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1580829000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2123000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1260000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1285293000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1255932000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
302740000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
326204000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
324519000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
352735000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
967000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
174000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26798000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17056000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6640000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6911000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
536000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
33438000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
23431000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32471000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23257000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
3110000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
207000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29361000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23050000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47214
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47214
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46739
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46739
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29361000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23050000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
863000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1782000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28498000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24832000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29361000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23050000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
726000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
811000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1256000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-772000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
536000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4340000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3153000
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
967000
CY2022Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
71000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2722000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7148000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3448000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2738000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1325000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4273000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28569000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24534000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
127000000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27845000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
73846000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
16890000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
585000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
575000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
52569000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10380000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
694000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
304000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
694000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
304000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24694000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13850000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29429000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39143000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54123000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25293000
CY2023Q1 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
134000
CY2022Q1 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
53000
CY2023Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(1)  Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared by Celldex Therapeutics, Inc. (the “Company” or “Celldex”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These interim financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and should be read in conjunction with the audited financial statements for the year ended December 31, 2022, which are included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2023. In the opinion of management, the interim financial statements reflect all normal recurring adjustments necessary to fairly state the Company’s financial position and results of operations for the interim periods presented. The year-end condensed balance sheet data presented for comparative purposes was derived from audited financial statements but does not include all disclosures required by U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future interim period or the fiscal year ending December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At March 31, 2023, the Company had cash, cash equivalents and marketable securities of $278.4 million. The Company has had recurring losses and incurred a loss of $29.4 million for the three months ended March 31, 2023. Net cash used in operations for the three months ended March 31, 2023 was $28.6 million. The Company believes that the cash, cash equivalents and marketable securities at the filing date of this Quarterly Report on Form 10-Q will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months from the date of issuance of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the next twelve months and beyond, the Company may take further steps to raise additional capital to meet its long-term liquidity needs including, but not limited to, one or more of the following: the licensing of drug candidates with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. Although the Company has been successful in raising capital in the past, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company’s negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financings may be dilutive to the Company’s stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company’s economic potential from products under development. The Company’s ability to continue funding its planned operations beyond twelve months from the issuance date is also dependent on the timing and manner of payment of amounts due under the Settlement Agreement with Shareholder Representative Services LLC (“SRS”) (refer to Note 13), in the event that the Company achieves the milestones related to those payments. The Company, at its option, may decide to pay those milestone payments in cash, shares of its common stock or a combination thereof. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay ongoing or anticipated clinical trials, license out programs earlier than expected, raise funds at a significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company.</p>
CY2023Q1 us-gaap Investments And Cash
InvestmentsAndCash
278400000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29400000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28600000
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
0
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
500000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
224737000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
59000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
532000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
224264000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
276859000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1341000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
275523000
CY2023Q1 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2022Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2023Q1 us-gaap Interest Receivable
InterestReceivable
600000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
800000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
326204000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
694000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4340000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
863000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29361000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
302740000
CY2023Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
27200000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
27200000
CY2023Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1613000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1613000
CY2023Q1 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
3720000
CY2022Q4 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
4650000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
48000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
60000
CY2023Q1 us-gaap Other Liabilities
OtherLiabilities
5381000
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
6323000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
978000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
990000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4403000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5333000
CY2023Q1 cldx Stock Issued Remaining Authorized Amount
StockIssuedRemainingAuthorizedAmount
50000000.0
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
419476000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
304000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3153000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1782000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23050000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
398101000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
33.25
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
78100000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
42000000.0
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
38300000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4340000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3153000
CY2023Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0.0
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
100000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
100000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0.0
CY2023Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1600000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1600000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4967764
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4064557
CY2022Q2 cldx Business Combination Contingent Consideration Settlement Agreement Amount Paid
BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid
15000000.0

Files In Submission

Name View Source Status
cldx-20230331_def.xml Edgar Link unprocessable
0001104659-23-055992-index-headers.html Edgar Link pending
0001104659-23-055992-index.html Edgar Link pending
0001104659-23-055992.txt Edgar Link pending
0001104659-23-055992-xbrl.zip Edgar Link pending
cldx-20230331.xsd Edgar Link pending
cldx-20230331x10q.htm Edgar Link pending
cldx-20230331xex31d1.htm Edgar Link pending
cldx-20230331xex31d2.htm Edgar Link pending
cldx-20230331xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
cldx-20230331_cal.xml Edgar Link unprocessable
cldx-20230331_lab.xml Edgar Link unprocessable
cldx-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cldx-20230331x10q_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending